Argenx highlights fcrn leadership with long-term data and transformational patient outcomes at the american academy of neurology 2025 annual meeting

Amsterdam, the netherlands – march 7, 2025 – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for vyvgart® (efgartigimod alfa-fcab) and vyvgart® hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the american academy of neurology (aan) annual meeting, taking place in san diego, ca from april 5-9, 2025.
ARGX Ratings Summary
ARGX Quant Ranking